#Formycon
Vous avez repéré une action qui cote bien en dessous de ce que valent ses comptes, et vous vous demandez si c'est une aubaine ou un piège. Notre article prend le cas Formycon, entre un cours de 15,28 euros et 22,58 euros de fonds propres par action.
Formycon cote 15,28 euros pour des fonds propres de 22,58 euros par action
Le fabricant allemand de biosimilaires affiche une action sous sa valeur comptable, mais des pertes persistantes et un cash en baisse. Ce que disent les ratios, et ce qu'ils ne disent pas.
vigiebourse.fr
November 17, 2026 at 5:25 AM
Formycon AG nimmt zahlungsunwirksame Wertminderungen auf FYB201 und FYB202 vor und passt die Prognose für das be [...] // #Würmtal // marketscreener.com
November 6, 2026 at 3:20 PM
Formycon lädt zur Telefonkonferenz zum Neunmonatsergebnis 2026 ein und gibt Teilnahme an internationalen Invest [...] // #Würmtal // marketscreener.com
November 5, 2026 at 3:20 PM
Formycon and Zydus File First Publicly Disclosed Keytruda® aBLA Along with PGR
Formycon and Zydus File First Publicly Disclosed Keytruda® aBLA Along with PGR
On October 13, 2026, Formycon and Zydus announced the FDA accepted for review their aBLA for FYB206 (pembrolizumab), a proposed biosimilar of...
www.jdsupra.com
October 27, 2026 at 4:59 PM
Formycon and Zydus File First Publicly Disclosed Keytruda® aBLA Along with PGR
Formycon and Zydus File First Publicly Disclosed Keytruda® aBLA Along with PGR
On October 13, 2026, Formycon and Zydus announced the FDA accepted for review their aBLA for FYB206 (pembrolizumab), a proposed biosimilar of...
www.jdsupra.com
October 27, 2026 at 4:59 PM
Formycon and Zydus File First Publicly Disclosed Keytruda® aBLA Along with PGR
Formycon and Zydus File First Publicly Disclosed Keytruda® aBLA Along with PGR
On October 13, 2026, Formycon and Zydus announced the FDA accepted for review their aBLA for FYB206 (pembrolizumab), a proposed biosimilar of...
www.jdsupra.com
October 27, 2026 at 4:59 PM
FDA Accepts Formycon and Zydus’ Proposed Pembrolizumab Biosimilar for Review
FDA Accepts Formycon and Zydus’ Proposed Pembrolizumab Biosimilar for Review
On October 13, 2026, Formycon and Zydus announced that the FDA accepted for review the Biologics License Application for FYB206, a proposed...
www.jdsupra.com
October 22, 2026 at 6:33 PM
FDA Accepts Formycon and Zydus’ Proposed Pembrolizumab Biosimilar for Review
FDA Accepts Formycon and Zydus’ Proposed Pembrolizumab Biosimilar for Review
On October 13, 2026, Formycon and Zydus announced that the FDA accepted for review the Biologics License Application for FYB206, a proposed...
www.jdsupra.com
October 22, 2026 at 6:33 PM
FDA Accepts Formycon and Zydus’ Proposed Pembrolizumab Biosimilar for Review
FDA Accepts Formycon and Zydus’ Proposed Pembrolizumab Biosimilar for Review
On October 13, 2026, Formycon and Zydus announced that the FDA accepted for review the Biologics License Application for FYB206, a proposed...
www.jdsupra.com
October 22, 2026 at 6:33 PM
Biosimilar manufacturers bet on golden years to come
Biosimilar manufacturers bet on golden years to come
Companies like Sandoz and Formycon will significantly expand their portfolios
dlvr.it
October 19, 2026 at 2:39 AM
Hersteller von Biosimilars setzen auf kommende goldene Jahre: Unternehmen wie Sandoz und Formycon werden ihr Portfolio erheblich erweitern.
Hersteller von Biosimilars setzen auf kommende goldene Jahre
Unternehmen wie Sandoz und Formycon werden ihr Portfolio erheblich erweitern.
dlvr.it
October 19, 2026 at 6:32 AM
Médicaments biosimilaires : La prochaine ruée vers l’or de l’industrie pharmaceutique
Médicaments biosimilaires : La prochaine ruée vers l’or de l’industrie pharmaceutique
Des entreprises telles que Sandoz et Formycon vont considérablement élargir leur portefeuille The post Médicaments biosimilaires : La prochaine ruée vers l’or de l’industrie pharmaceutique appeared first on Rapporteur FR .
www.rapporteur.com
October 19, 2026 at 2:08 PM
Los fabricantes de biosimilares apuestan por un futuro prometedor
Los fabricantes de biosimilares apuestan por un futuro prometedor
Empresas como Sandoz y Formycon ampliarán considerablemente sus carteras de productos The post Los fabricantes de biosimilares apuestan por un futuro prometedor appeared first on Rapporteur ES.
dlvr.it
October 19, 2026 at 6:33 AM
Ich habe nach den jüngsten US-News mit #Formycon-CEO Stefan Glombitza ausführlicher über das #Keytruda-Biosimilar #FYB206 gesprochen, das einen Milliardenmarkt erobern soll.

Formycon: „Wir gehören zur Spitzengruppe“ - Interview www.4investors.de/nachrichten/...
Formycon: „Wir gehören zur Spitzengruppe“ - Interview
Formycon-CEO Stefan Glombitza im 4investors.de-Interview über das Keytruda-Biosimilar FYB206, die FDA-Zulassung, Marktchancen und KI in der Entwicklung.
www.4investors.de
October 15, 2026 at 5:56 AM
First Keytruda biosimilar accepted for FDA review. The world's best-selling drug ($31.7B in 2025) finally has a challenger in line. Decision expected around Q3 2027. https://thisnewsroom.com/keytruda-biosimilar-fda-review-zydus-formycon/
October 14, 2026 at 1:00 AM
Formycon und Zydus: FDA nimmt FYB206 als erstes öffentlich bekannt gegebenes Keytruda®-Biosimilar zur Prüfung an // #Würmtal // marketscreener.com
October 13, 2026 at 2:20 PM
FDA Accepts Review of Zydus Keytruda Biosimilar Application #MarketUpdates Follow Us for more
FDA Accepts Review of Zydus Keytruda Biosimilar Application
The FDA has accepted for review the first publicly announced biosimilar application referencing Merck's Keytruda, developed by Formycon and licensed to
quantli.com
October 13, 2026 at 10:02 PM
Zydus holds exclusive US and Canada commercialization rights under a December 2025 licensing agreement, and Formycon has earned a mileston...

🚀 Free alerts → https://gunpowderalerts.in/go?utm_source=bluesky&utm_medium=social&utm_campaign=high_priority_filing
#IndiaMarkets #Healthcare #MarketNotice
October 13, 2026 at 4:47 AM
Zydus Lifesciences Limited — Market Notice

Zydus Lifesciences and Formycon AG jointly announced that the USFDA has accepted for review the Biologics License Application for FYB206, a proposed biosimilar to Keytruda (pembrolizumab), which the companies believe is the first publicly...

🧵 continued ↓
October 13, 2026 at 4:47 AM
Hier ist wieder unser wöchentlicher Überblick über diverse demnächst anstehende Hauptversammlungen. Nehmt bitte euer Stimmrecht wahr oder delegiert es an euch vertrauenswürdige Aktionärsvertreter! www.4investors.de/nachrichten/... #aktien #aktionärsrechte #hauptversammlung #4investors
HV-Kalender: ams Osram, Eurokai, Evotec, Exasol, Formycon, Jenoptik, Marinomed, Masterflex, OHB, Renk
Die Hauptversammlung: Das höchste Organ einer Aktiengesellschaft. Die ausführliche 4investors.de-Übersicht informiert über die HV-Termine der nächsten Wochen.
www.4investors.de
June 7, 2026 at 5:37 PM